Sporotrichosis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 13: Line 13:
|Uncomplicated cutaneous
|Uncomplicated cutaneous
|
|
* Itraconazole [200 mg PO qd]
* [[Itraconazole]] 200 mg PO qd
|
|
* Itraconazole [200 mg PO bid],  
* [[Itraconazole]] 200 mg PO bid, {{Or}}
* terbinafine [500 mg PO bid],  
* [[Terbinafine]] [500 mg PO bid], {{Or}}
* SSKI [increasing doses],
* [[Potassium iodide|SSKI]] increasing doses], {{Or}}
* fluconazole [400-800 mg PO qd],  
* [[Fluconazole]] [400-800 mg PO qd], {{Or}}
* '''<u>OR</u>''' local hyperthermia
* Local hyperthermia
|Continue treatment for 2-4 weeks after lesions resolve.
|Continue treatment for 2-4 weeks after lesions resolve.
|-
|-

Revision as of 14:18, 13 January 2016

Sporotrichosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sporotrichosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Treatment

Medical Therapy

Surgery

Prevention

Case Studies

Case #1

Sporotrichosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sporotrichosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sporotrichosis medical therapy

CDC on Sporotrichosis medical therapy

Sporotrichosis medical therapy in the news

Blogs on Sporotrichosis medical therapy

Directions to Hospitals Treating Sporotrichosis

Risk calculators and risk factors for Sporotrichosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alison Leibowitz [2]

Treatment

Form Primary Line of Treatment Alternative Treatment Remarks/Other
Uncomplicated cutaneous Continue treatment for 2-4 weeks after lesions resolve.
Osteoarticular
  • Itraconazole [200 mg PO bid]
  • Limposomal amphotericin B [3-5 mg/kg PO qd]
  • OR deoxycholate amphotericin B [0.7-1 mg/kg PO qd] until symptom resolution
For a total of 12 months, switch to itraconazole after resolution/end of treatment.
Pulmonary
  • Limposomal amphotericin B [3-5 mg/kg PO qd],
  • THEN followed by itraconazole [200 mg PO bid]
  • Deoxycholate amphotericin B [0.7-1 mg/kg PO qd],
  • THEN followed by itraconazole [200 mg PO bid] upon symptom resolution
Treat less sever cases with a 12 month regimen of itraconazole.
Meningeal
  • Limposomal amphotericin B [3-5 mg/kg PO qd],
  • THEN followed by itraconazole [200 mg PO bid]
  • Deoxycholate amphotericin B [0.7-1 mg/kg PO qd],
  • THEN followed by itraconazole [200 mg PO bid] upon symptom resolution
Precise length of amphotericin B treatment varies. Suppressive treatment with itraconazole is necessary.
Dissimated
  • Limposomal amphotericin B [3-5 mg/kg PO qd],
  • THEN followed by itraconazole [200 mg PO bid.]
  • Deoxycholate amphotericin B [0.7-1 mg/kg PO qd],
  • THEN followed by itraconazole [200 mg PO bid] upon symptom resolution
Continue amphotericin B treatment until patient shows marked improvement for a minimum of 12 months. Suppressive treatment with itraconazole is necessary.
Sporotrichosis in pregnant women
  • Treat with limposomal amphotericin B [3-5 mg/kg PO qd]
  • OR deoxycholate amphotericin B [0.7-1 mg/kg PO qd] only for severe cases of sporotrichosis.
  • In cases of uncomplicated cutaneous, treat with only hyperthermia.
It is preferable to defer treatment in uncomplicated cases.
Sporotrichosis in Children
  • Itraconazole [6-10 mg PO qd to a max of 400 mg PO qd] for mild cases
  • Deoxycholate amphotericin B [0.7-1 mg/kg PO qd] for severe cases
  • SSKI [increasing doses equivalent to half the adult dose], continuing treatment for 2-4 weeks after resolution of symptoms.

[1]

References

  1. Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America (2007). "Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (10): 1255–65. doi:10.1086/522765. PMID 17968818.